Acute Lymphocytic Leukemia in Children: How Families Are Guided Through the Care Pathway

The whiteboard in the small consulting room has five boxes drawn on it, joined by arrows. A pediatric oncologist is filling them in while a father holds a sleeping four-year-old and a mother writes down every word. Induction. Consolidation. Interim maintenance. Delayed intensification. Maintenance. Three days ago this family thought they were dealing with a stubborn virus and some odd bruises.

That whiteboard is, in effect, the ALL treatment pathway for children: a sequence refined over decades of cooperative trials, adapted to each child’s risk group, and designed to be explained one box at a time. Most parents remember almost nothing from the first conversation except the word leukemia. The second conversation, usually the next morning, is when the map starts to make sense.

This explainer walks that map at a reader’s pace: what each phase is for, how long the stretches typically last, what the following weeks look like at home, and which questions are worth asking before signing the consent forms. It corrects a few myths along the way, because families deserve evidence rather than folklore.

What is acute lymphocytic leukemia in children?

Leukemia is a cancer of the blood-forming cells in bone marrow, the spongy tissue inside bones where blood is made. In acute lymphocytic leukemia, also written as acute lymphoblastic leukemia and shortened to ALL, the cells that go wrong are lymphoblasts: immature versions of the white blood cells that would normally grow into infection-fighting lymphocytes. Instead of maturing, they copy themselves, crowd the marrow and spill into the bloodstream.

That crowding explains most of what parents notice before a diagnosis. Fewer red cells means pallor and a child who wants to be carried. Fewer platelets means bruises in odd places. Fewer working white cells means infections that will not clear. None of these is specific to leukemia, which is why a blood count, not a list of symptoms, is what settles the question.

ALL is the most common cancer of childhood, and MedlinePlus notes that it occurs most often in children between about 2 and 5 years old. The disease has two main lineages. B-cell ALL, the more common form, arises from cells destined to become antibody-producing B lymphocytes. T-cell ALL arises from cells headed toward the thymus, and it sometimes presents with a mass in the chest. The distinction matters because it shapes the intensity of treatment.

Why a particular child develops ALL is usually unknowable. It is not contagious, and it is not caused by anything a parent did or failed to do. A small number of genetic conditions, including Down syndrome, raise the risk, but most children with ALL have none of them. The word acute signals that the disease progresses over days and weeks rather than years, which is why treatment begins within days of confirmation rather than after a long period of deliberation.

How is childhood ALL diagnosed and sorted into risk groups?

The diagnosis starts with a complete blood count and a look at a blood smear under the microscope. Confirmation comes from a bone marrow aspirate and biopsy: a thin needle draws a sample of marrow from the back of the hip bone, done under sedation or general anesthesia in children so the procedure itself is not remembered.

Several laboratory tests then run on that sample. Flow cytometry reads the protein markers on the surface of each cell and tells B-cell from T-cell disease. Cytogenetic and molecular tests examine the chromosomes and genes inside the leukemia cells for changes that predict how the disease will behave, such as the Philadelphia chromosome, a swap of material between two chromosomes that creates an abnormal growth signal. A lumbar puncture, in which a small sample of spinal fluid is taken from the lower back, checks whether leukemia cells have reached the fluid around the brain and spinal cord. A chest X-ray looks for a mass near the heart in T-cell disease.

From these results the team assigns a risk group. According to the National Cancer Institute, the factors carrying the most weight are the child’s age at diagnosis, the white blood cell count at diagnosis, the subtype, the genetic findings, whether the central nervous system is involved, and how quickly the leukemia responds to the first phase of treatment. That last factor is measured as minimal residual disease, or MRD: leukemia cells too few to see under a microscope but detectable by highly sensitive tests.

Risk grouping is not a verdict. It is a tool for matching intensity to need, so that a child with lower-risk disease is spared unnecessary toxicity and a child with higher-risk disease receives enough. The group can shift after induction, and families should expect the team to revisit it.

What does the ALL treatment pathway for children actually involve?

At its core, the pathway is combination chemotherapy delivered in planned phases. Chemotherapy medicines damage cells that are dividing rapidly. Leukemia cells divide constantly and are poor at repairing damage, so they die in far greater numbers than healthy cells. Healthy tissues that also divide quickly, such as hair follicles, the lining of the gut and normal marrow, get caught too, which is where most side effects come from.

Several medicines with different mechanisms are given together or in sequence. Corticosteroids, a class of medicines related to the body’s own stress hormones, kill lymphoblasts directly. Others interfere with cell division, block the building blocks of DNA, or starve the leukemia cells of an amino acid they cannot make for themselves. Using several at once makes it much harder for a resistant population to survive and regrow.

Children are generally treated on standardized protocols, which are written plans specifying which medicines, in which order, with which checks. Many families are invited to enroll in a clinical trial, meaning a study comparing the current standard against a carefully chosen refinement, with consent and the freedom to decline. The Mayo Clinic and the NHS both describe the same broad sequence: induction, consolidation or intensification, and maintenance, with therapy directed at the central nervous system running alongside.

Two additions apply in specific situations. Children whose leukemia carries the Philadelphia chromosome usually receive a targeted medicine from the tyrosine kinase inhibitor class, which blocks the abnormal growth signal. Immunotherapies, which recruit the immune system against leukemia cells, are used in some higher-risk or relapsed settings. Which of these applies to a given child, and when, is a decision for the treating team based on the laboratory findings.

Induction and the intensive months: what happens in the first phases?

Induction is the first phase, and its single goal is remission. The National Cancer Institute defines remission in ALL as a marrow with fewer than 5 percent blasts, recovering normal blood counts and no signs of leukemia elsewhere. Induction typically lasts about four weeks, often beginning with a hospital stay of several days while the child is stabilized and the family is taught what comes next.

The medicines in this phase usually include vincristine, a corticosteroid and asparaginase, with an anthracycline added for children in higher-risk groups. The team also manages what happens when large numbers of leukemia cells die at once: their breakdown products can strain the kidneys, a situation called tumor lysis syndrome, so fluids and monitoring are part of the plan. Transfusions of red cells or platelets are common while the marrow recovers.

At the end of induction, the marrow is sampled again and MRD is measured. This result, more than almost any other, tells the team whether the planned intensity is right.

Remission is a microscope word, not a finish line. Billions of leukemia cells can remain unseen, which is why consolidation and delayed intensification follow. These blocks use different combinations, commonly including methotrexate, cyclophosphamide, cytarabine and mercaptopurine, to attack cells that survived the first assault. Delayed intensification repeats an induction-like block later in the year for the same reason.

Throughout these months, medicine is also given directly into the spinal fluid through lumbar punctures. This intrathecal chemotherapy is needed because most drugs given by vein cross poorly into the brain and spinal cord, leaving a sanctuary where leukemia could hide. Radiation to the brain, once routine, is now reserved for a small minority of children, according to the National Cancer Institute. Blood counts fall to their lowest during the intensive months, and hospital admissions for fever are expected rather than exceptional.

Childhood ALL maintenance therapy: the long, quieter stretch

Maintenance is the longest phase and the least dramatic, which is exactly the point. Once the intensive blocks are done, treatment shifts to a lower-intensity routine aimed at slow-dividing leukemia cells that intensive chemotherapy tends to miss. The NHS describes this phase as lasting around two years, and it is the reason the total pathway stretches so far beyond the first hospital stay.

The routine typically combines a daily oral chemotherapy medicine, a weekly oral one, periodic short pulses of a corticosteroid with an intravenous dose of vincristine, and intrathecal chemotherapy at intervals that grow further apart. Blood counts are checked regularly, and the prescribing team adjusts the plan according to those counts. Parents should never change the schedule themselves; if a dose is missed or vomited, the right response is a call to the team, not a guess.

The evidence behind this long tail is not sentimental. Trials over several decades found that shortening or omitting maintenance increased the chance of relapse, which is why every modern childhood protocol keeps it, as the National Cancer Institute’s treatment summary notes.

Life during maintenance looks recognizably normal for many families. Children return to school, play sports and see friends. Infection precautions continue, because the immune system is still suppressed: live vaccines are deferred, and any contact with chickenpox or measles needs a prompt call to the team. Fevers still require urgent assessment.

The psychological texture of maintenance is its own challenge. The crisis has passed, the casseroles have stopped arriving, and yet a pill must be given every evening for two years. Many parents describe this as the phase where support from social workers, psychologists and other families matters most.

Who follows the standard ALL treatment protocol for kids, and who takes a different route?

Most children with ALL are treated on a standard-risk or high-risk arm of a cooperative-group protocol. Standard-risk children are usually between 1 and 9 years old at diagnosis, have a lower white blood cell count, B-cell disease, favorable genetic findings and a rapid fall in MRD after induction; these criteria come from the National Cancer Institute’s risk classification. High-risk children may be older than 10, have a very high white cell count, T-cell disease, unfavorable genetics or a slower early response. They receive more intensive blocks, often with additional intrathecal doses.

Several groups are routed differently from the start. Infants under 1 year have a biologically distinct disease, frequently driven by a rearrangement of the KMT2A gene, and are treated on dedicated infant protocols. Children with the Philadelphia chromosome have a tyrosine kinase inhibitor added to chemotherapy. Children with Down syndrome are more sensitive to certain medicines and typically have their plan adjusted to reduce toxicity while preserving effect.

Because ALL is acute, no child is asked to wait in the sense of watchful observation. What does happen is a short pause of days to correct a serious infection, kidney strain or bleeding before the first dose, and scheduled pauses during treatment when blood counts need to recover. These are built into protocols rather than signs of a problem.

Stem cell transplant, in which the child’s marrow is replaced with donor cells after very intensive treatment, is not part of the initial pathway for most children. The National Cancer Institute describes it as an option for a small group with very high-risk features or for leukemia that has come back. Whether any of these routes applies is a judgment the treating team makes from the full picture of a child’s disease, not from any single test.

How long does the ALL treatment pathway for children usually take?

Families ask this on day one, and they deserve a straight answer with an honest caveat. The NHS and the Mayo Clinic both describe total treatment for childhood ALL as typically lasting about two to three years. Almost all of that is the maintenance phase; the intensive part is measured in months.

Phase	Typical length	Mostly delivered	Main purpose
Induction	About 4 weeks	Hospital, then clinic	Reach remission; measure early response (MRD)
Consolidation and intensification blocks	Several months	Clinic with some admissions	Destroy residual cells; protect the central nervous system
Maintenance	Around 2 years	Home and outpatient clinic	Eliminate slow-dividing residual cells; prevent relapse
Follow-up after therapy	Years, with visits spacing out	Outpatient clinic	Watch for relapse; monitor growth and late effects

These ranges are drawn from the phase descriptions published by the National Cancer Institute and the NHS. They are typical, not promised. A child whose counts recover slowly may have blocks delayed by a week or two at a time. A serious infection can pause treatment. A change in risk group after induction can lengthen the intensive stretch. Some protocols historically continued maintenance longer for boys than for girls; whether that applies depends on the specific protocol the team is following.

One useful mental adjustment: think of the calendar in two parts. The first several months are the marathon of appointments, admissions and low counts. The remaining years are a routine that gradually loosens. Planning school, work and childcare around those two very different rhythms, rather than around a single two-year block, tends to serve families better.

What do the first weeks look like for the family?

The first admission is dense. Within a day or two of diagnosis, the child usually has a central venous line placed under anesthesia: a soft tube that sits in a large vein and allows blood draws and medicines without repeated needle sticks. Nurses teach parents to care for it, because most line problems are preventable with clean technique.

A cast of people appears quickly. The pediatric oncologist leads the plan. A nurse specialist becomes the family’s day-to-day contact. Pharmacists check every dose against the protocol. A social worker helps with work, benefits and siblings. Child life specialists prepare the child for procedures with play. A psychologist, dietitian and school liaison often join within the first weeks. Ask each person what they do; it makes the crowd less bewildering.

Home routines shift around infection risk. Hand hygiene becomes a household habit. During weeks of low white cell counts, crowded indoor spaces and people with obvious illness are avoided, and food is handled with extra care. A reliable thermometer lives on the kitchen counter, and the family knows which number to call at three in the morning. Pets can usually stay, with sensible precautions the team will describe.

Corticosteroid weeks bring their own weather: a child who is ravenous, tearful, wakeful and short-tempered in a single afternoon. Knowing this is the medicine, not the child, helps everyone.

Siblings notice everything and are often the last to be told anything. Age-appropriate honesty, a named adult who is theirs, and permission to keep their own lives running matter more than perfect words. Many parents keep a notebook of questions and results; by week three it is usually the most-consulted object in the house.

Which side effects do families most often ask about?

Side effects follow from mechanism, and understanding the mechanism makes them less frightening. Because chemotherapy suppresses normal marrow, children spend stretches with low neutrophils, the white cells that fight bacteria; this state, called neutropenia, is why fever is treated as an emergency. Low red cells cause fatigue and pallor, and low platelets cause bruising and nosebleeds; both are managed with transfusion when needed.

The gut lining renews itself quickly and so is vulnerable. Mouth sores, nausea, appetite changes and diarrhea or constipation are common, and anti-nausea medicines are given preventively rather than after the fact. Hair thins or falls out during the intensive months and regrows during maintenance; its loss says nothing about how the leukemia is responding.

Individual medicines carry recognizable signatures, which the team monitors for:

• Vincristine can irritate nerves, causing tingling in the hands and feet, jaw pain, a drooping eyelid or constipation.
• Asparaginase can inflame the pancreas, affect clotting and provoke allergic reactions, so blood tests and observation follow each dose.
• Corticosteroids alter mood, appetite, sleep, blood sugar and, over time, bone and muscle strength.
• Anthracyclines can affect the heart muscle, so heart ultrasounds are scheduled before and during treatment.
• Methotrexate can cause mouth sores and temporary changes in liver blood tests.

Most of these effects are temporary and reversible, and the Cleveland Clinic and Mayo Clinic descriptions of ALL treatment emphasize that supportive care has improved alongside the chemotherapy itself. The team’s job is to watch, adjust and treat complications early; the family’s job is to report changes promptly and never to alter a schedule on their own. A short, specific description, such as when a symptom started and what makes it worse, is more useful to the team than a worried summary.

How often does ALL come back, and what happens if it does?

Relapse means leukemia cells reappear after remission was achieved. Parents want a number, and the honest answer is that the figure depends heavily on risk group, genetics and early MRD response, so a single national percentage would mislead more than inform. The National Cancer Institute’s treatment summary makes clear that most children who reach remission on modern protocols stay in remission, and that relapse affects a minority. Ask the team for the estimate that applies to your child’s group; they will have it.

Timing follows a pattern. Relapse is most likely during treatment or in the first few years after it ends, which is why follow-up visits are closest together then. Late relapses many years out are uncommon. The marrow is the most frequent site, but leukemia can also return in the spinal fluid or, in boys, the testes, sometimes in combination.

If relapse happens, the pathway restarts with a different map. Options the team may discuss include a second course of intensive chemotherapy using different combinations, a stem cell transplant from a donor, and immunotherapies. Two immunotherapy approaches now used in relapsed childhood B-cell ALL are CAR T-cell therapy, in which a child’s own T cells are collected, genetically engineered to recognize leukemia cells and returned by infusion, and bispecific antibodies, laboratory-made proteins that hold a T cell and a leukemia cell together so the immune cell can attack. Clinical trials are frequently part of the conversation.

Which route is chosen depends on where and when the relapse occurred, the genetics of the returning cells and how the child tolerated earlier treatment. These are among the most consequential decisions in pediatric oncology, and they belong with the treating team, who will lay out risks and alternatives in detail.

What does follow-up look like after treatment ends?

The last dose of maintenance is a milestone most families mark with something: a bell, a cake, a very long sleep. What follows is a structured period of surveillance rather than an abrupt goodbye. Blood counts are checked at visits that start close together and space out over several years, in line with the relapse timing described by the National Cancer Institute. Bone marrow tests are not routine after therapy unless counts or symptoms raise a question.

Immune recovery takes months. The team advises when routine vaccinations can resume and whether earlier doses need repeating, and until then the household precautions of the maintenance years continue in a lighter form.

Longer term, children move into survivorship care, often in a dedicated clinic. The focus shifts to late effects, meaning health problems that can emerge years after treatment. The main areas the team watches, drawn from the National Cancer Institute’s guidance, are:

• Heart function, particularly in children who received anthracyclines, monitored with periodic heart ultrasounds.
• Bone health and joints, because corticosteroids can reduce bone density and occasionally damage the blood supply to bone.
• Growth and puberty, checked at each visit.
• Learning, attention and processing speed, especially in children treated very young or with radiation to the brain; schools can be asked for support.
• Fertility, which standard ALL chemotherapy rarely affects but which is discussed openly.
• A small risk of second cancers, which is why unusual symptoms are always investigated.

Families should leave the final treatment visit with a written summary of everything the child received and a schedule of what to monitor, sometimes called a survivorship care plan. It becomes the document that future doctors, in adolescence and adulthood, will rely on. Emotional recovery is real work too; anxiety before follow-up blood tests is common in parents and survivors alike, and psychology support remains available for it.

What people often get wrong about childhood ALL

A diagnosis attracts advice, and some of it is wrong in ways that cause harm. These are the misunderstandings oncology teams hear most, corrected with what the evidence shows.

Someone must have caused it. No lifestyle, diet, cell phone, food additive or missed doctor’s visit is known to cause childhood ALL. The Mayo Clinic and MedlinePlus are explicit that the cause in most children is unknown, with a small contribution from certain inherited conditions. Guilt is understandable and almost always misplaced.

It is contagious, or siblings are likely to get it. Leukemia cannot pass from child to child. Siblings are not routinely tested, because their risk is very low; a sibling is tested as a potential stem cell donor only if the team recommends that route.

Remission means treatment is over. Remission is achieved within about a month, yet treatment continues for years. Stopping early because a child looks well is one of the strongest known routes to relapse.

Hair loss means the disease is winning. Hair loss reflects the medicines’ effect on follicles and says nothing about how the leukemia is responding. MRD results carry that information.

Special diets, supplements or clinics abroad can treat leukemia. No diet, herbal product or high-dose vitamin has been shown to treat ALL, and some interfere with chemotherapy or increase infection risk. Good nutrition supports a child through treatment; it does not replace it. Anything a child takes, including vitamins, should be cleared with the team.

The child must live in a bubble. Precautions are targeted to low-count periods. School, friends and outdoor play return during maintenance for most children, and the team will say when.

Childhood ALL is treated like adult leukemia. Children tolerate and respond to intensive chemotherapy differently, and pediatric protocols are built on decades of trials in children specifically. Comparisons with an adult relative’s experience rarely apply.

Questions to ask your care team

Consultations move fast, and the questions that matter most tend to surface in the car afterwards. Bringing a written list changes that. The list below is a starting point; cross out what does not apply and add what keeps you awake.

• Which subtype of ALL does my child have, and which risk group has been assigned so far?
• Which protocol is being followed, and is a clinical trial part of it? What would change if we chose not to enroll?
• What did the genetic tests show, and do any results change the plan?
• When will MRD be measured, and how will the result affect the next phase?
• Roughly how long is each phase expected to last for a child in this group?
• Which side effects should we expect from each medicine, and which ones need an urgent call?
• What is the exact number to call at night and at weekends, and what should we say when we call?
• How will the central line be cared for at home, and who teaches us?
• What infection precautions apply now, and how will they change during maintenance?
• When can my child return to school or daycare, and can someone speak to the school?
• Which vaccines are paused, and what should we do if there is chickenpox or measles in the class?
• What support is available for siblings and for us as parents?
• How is fertility discussed for a child of this age, and is anything recommended before treatment?
• Who coordinates care if we are admitted to a different hospital in an emergency?
• What will follow-up look like after treatment ends, and who provides long-term care?

Ask for answers in writing where possible, and ask again if an answer did not land. Teams expect repetition; a question asked three times across three weeks is a sign of a family engaging with the plan, not a nuisance. If a question falls outside the team’s expertise, they can refer to someone whose expertise it is.

When to call your doctor

Children on ALL treatment have suppressed immune systems and low platelets for long stretches, so problems that would be minor in another child can escalate within hours. Every family is given a direct line to the oncology team that works around the clock. Use it early; no one on the other end will think a call was unnecessary.

Call immediately, day or night, for any of the following:

• A fever at or above the threshold your team has given you, or shaking chills even without a measured fever. During neutropenia this is treated as an emergency and usually means going to the hospital for assessment and intravenous antibiotics.
• Redness, swelling, pain or leakage around the central line, or a line that will not flush.
• Bleeding that does not stop within a few minutes, blood in urine or stool, widespread pinpoint red spots on the skin, or a nosebleed lasting longer than the team advised.
• Difficulty breathing, rapid breathing, or a bluish tinge to the lips.
• A severe headache, repeated vomiting, a stiff neck, unusual drowsiness, confusion, weakness on one side, or a seizure.
• Severe abdominal pain, especially after asparaginase, or pain with a swollen belly.
• Swelling, pain or color change in one arm or leg, which can signal a blood clot.
• Close contact with anyone who has chickenpox, shingles or measles, even if the child seems well.
• Inability to keep down oral medicines, or a dose given wrongly or missed.
• Passing much less urine than usual, or refusing all fluids.
• A new rash, mouth sores that prevent drinking, or any sudden change that worries you.

When you call, have the child’s name, protocol phase, current temperature, the last dose given and any allergies ready. If a child collapses, has a seizure lasting more than a few minutes, or cannot breathe, call emergency services first and the oncology team second. Trust the instinct that something is wrong; families are often the first to notice the change that matters.

Frequently asked questions

What is the treatment protocol for ALL in children?

A protocol is a written plan specifying which medicines are given, in what order, with which checks, and childhood ALL protocols follow the same broad structure: induction to reach remission, consolidation and delayed intensification to deepen it, and about two years of maintenance, with chemotherapy into the spinal fluid throughout. The exact arm depends on the child’s risk group, genetics and early response, and the treating team chooses it.

How long does the ALL treatment pathway for children take?

Treatment for childhood ALL typically lasts about two to three years in total, according to the NHS and the Mayo Clinic. Induction takes roughly four weeks, the intensive consolidation blocks span several months, and maintenance accounts for around two years. Individual timelines vary with risk group, count recovery and complications, so the team’s estimate for your child is the one to rely on.

What is the ALL relapse rate in children?

There is no single rate that fits every child, because the chance of relapse depends strongly on risk group, genetic findings and how quickly minimal residual disease cleared after induction. The National Cancer Institute’s summary indicates that most children who reach remission on modern protocols remain in it and that relapse affects a minority. Ask the treating team for the estimate that applies to your child’s specific group.

How often does ALL come back after treatment ends?

Relapse is most likely during treatment or within the first few years after it finishes, which is why follow-up visits are closest together in that window and then space out. Late relapses many years afterward are uncommon. The bone marrow is the most frequent site, but leukemia can also return in the spinal fluid or the testes, and the team’s surveillance plan is built around these patterns.

How long can a child live with acute lymphoblastic leukemia?

Untreated, ALL progresses over weeks, which is why treatment starts within days of diagnosis. With modern risk-adapted protocols, the outlook for children has improved markedly over recent decades, and most children who complete treatment go on to long-term remission, as the National Cancer Institute and NHS describe. Individual prognosis depends on subtype, genetics and early response, and the treating team can discuss what the evidence shows for your child.

What does remission mean in childhood ALL?

Remission means the bone marrow contains fewer than 5 percent blast cells, normal blood counts are recovering and there are no signs of leukemia elsewhere, using the National Cancer Institute definition. It is usually reached after induction. Remission does not mean treatment is finished; billions of cells can remain undetected, so consolidation and maintenance continue for years to prevent them from regrowing.

Why does my child need spinal injections during ALL treatment?

Most chemotherapy given by vein crosses poorly into the fluid around the brain and spinal cord, leaving a hiding place where leukemia cells could survive and later cause relapse. Intrathecal chemotherapy, delivered through a lumbar puncture into that fluid, closes the gap. It is given at intervals throughout treatment, usually under sedation in children, and has largely replaced radiation to the brain for most patients.

Can my child go to school during maintenance therapy?

Many children return to school during maintenance, when treatment intensity is lower and blood counts are more stable. The team will advise on timing, and a school liaison can brief teachers about infection precautions, fatigue and the need to report chickenpox or measles in the class. Absences for clinic visits and short admissions should be expected, and schools can often provide catch-up support.

Is childhood ALL hereditary or contagious?

Childhood ALL is not contagious and in the great majority of cases is not inherited. MedlinePlus and the Mayo Clinic note that the cause is usually unknown, with a small increase in risk from certain genetic conditions such as Down syndrome. Siblings are not routinely tested for leukemia because their risk is very low; they are tested only if the team is considering them as a stem cell donor.

What is minimal residual disease and why does it matter?

Minimal residual disease, or MRD, refers to leukemia cells that remain after treatment in numbers too small to see under a microscope but detectable with highly sensitive laboratory tests. Measured after induction, it is one of the strongest predictors of how the disease will behave. Children who clear MRD quickly may continue on standard intensity, while a slower clearance can lead the team to intensify treatment.

References

• MedlinePlus: Acute lymphoblastic leukemia (ALL)
• NHS: Acute lymphoblastic leukaemia, Treatment

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.